Positron Emission Tomography (PET) Nuclear Medicine Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Positron Emission Tomography (PET) Nuclear Medicine Market In 2029?
In recent times, the market size for nuclear medicine involving positron emission tomography (PET) has seen swift expansion. It is projected to rise from its value of $11.49 billion in 2024 to $13.16 billion in 2025, recording a compound annual growth rate (CAGR) of 14.5%. Past growth in this market is primarily due to factors such as an increasing number of cardiovascular disease cases, rising expenses in healthcare, a growth in urological diseases, a surge in the elderly population, and an augmented number of hospitals.
The market size for positron emission tomography (pet) nuclear medicine is projected to witness rapid expansion in the coming years, reaching a valuation of$22.52 billion by 2029 with a compound annual growth rate (CAGR) of 14.4%. The surge in the estimated period can be credited to aspects like increasing investments in research and development, a growing appeal for minimally invasive diagnostic methods, the expansion of worldwide healthcare infrastructure, surging demand for food and pharmaceutical packaging and an escalating incidence of cancer. Key market trends predicted for the period include technological progress, multi-modality diagnosis, the implementation of artificial intelligence, digital PET systems, and customized medicine.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Positron Emission Tomography (PET) Nuclear Medicine Market?
The growth of the positron emission tomography (PET) nuclear medicine market is predicted to be driven by the escalating prevalence of chronic diseases. These are health conditions that typically last for at least three months, often requiring ongoing medical intervention or impeding normal daily functions. The surge in chronic diseases can be linked to an aging population, a deficit in physical exercise, poor dietary habits, and environmental hazards. PET nuclear medicine aids the management of these chronic diseases by providing innovative imaging techniques that facilitate early detection, accurate diagnosis, and continuous monitoring of the conditions. For example, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported in February 2024 that there were about 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. Additionally, by 2050, the number of new cancer cases is projected to surpass 35 million, marking a 77% surge from the 2022 figure. Consequently, the rise in chronic diseases fuels the advancement of the positron emission tomography (PET) nuclear medicine market.
Which Key Market Segments Comprise the Positron Emission Tomography (PET) Nuclear Medicine Market and Drive Its Revenue Growth?
The positron emission tomography (pet) nuclear medicinemarket covered in this report is segmented –
1) By Type: F-18; Rb-82; Other Types
2) By Procedure: Diagnostic Procedures; Single Photon Emission Computed Tomography Procedures; Positron Emission Tomography Procedures; Therapeutic Procedures; Beta Emitter Procedures; Alpha Emitter Procedures; Brachytherapy Procedures
3) By Application: Oncology; Cardiology; Neurology; Other Applications
4) By End User: Hospitals; Diagnostic Centers; Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose); F-18 NaF (Sodium Fluoride); F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging; Rb-82 for Cardiac PET Stress Testing; Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11); N-13 (Nitrogen-13); O-15 (Oxygen-15); Ga-68 (Gallium-68)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19151&type=smp
Which Areas Are Leading Regions in the Positron Emission Tomography (PET) Nuclear Medicine Market Expansion Across the Globe?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) nuclear medicine marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering thePositron Emission Tomography (PET) Nuclear Medicine Market Direction?
Leading enterprises in the positron emission tomography (PET) nuclear medicine market are innovating advanced products like PET slice scanners that yield detailed images of metabolic functions. These scanners utilize positron emission tomography and progressive computing methodologies to generate comprehensive, layered pictures of metabolic operations in our system, assisting significantly in the detection and monitoring of diseases, primarily cancer. For example, in July 2024, Positron Corporation, an American nuclear medicine firm, introduced the NeuSight PET-CT 3D 64-slice scanner. This device signifies a milestone in imaging and diagnostic precision, seamlessly integrating high-end technology, patient comfort, and operational efficiency. It aims to revolutionize cardiac PET imaging and presents incomparable value and performance at an affordable price, making it perfect for cardiac and cancer clinical research. With enhanced data collection and revolutionary identifying technology, the NeuSight PET-CT increases scanning velocity and precision, offering comprehensive anatomical and functional imaging for heart, tumor, and brain studies in various molecular imaging applications.
View the full report here:
How Is the Positron Emission Tomography (PET) Nuclear Medicine Market Conceptually Defined?
Positron Emission Tomography (PET) nuclear medicine is a medical imaging method that employs radioactive materials to visualize and assess metabolic activities within the body. It uses a small amount of radioactive material called a radiotracer to detect changes at the cellular level, allowing doctors to diagnose diseases early.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19151
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
